Quantum-Si (NASDAQ:QSI) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Wall Street Zen upgraded Quantum-Si to “Hold” from “Sell.” The stock’s consensus rating is also “Hold,” with a consensus price target of $1.00.
• Quantum-Si shares opened at $0.74, near the lower end of their 12-month range of $0.69 to $3.10, while the company reported a quarterly loss of $0.11 per share and $0.34 million in revenue.
• Institutional investors own approximately 39.9% of QSI, with Vanguard, Geode Capital, State Street and others recently increasing their positions or initiating new stakes.

Quantum-Si (NASDAQ:QSI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on QSI. Weiss Ratings downgraded Quantum-Si from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday. Alliance Global Partners restated a "buy" rating on shares of Quantum-Si in a report on Friday, August 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $1.00.

Quantum-Si Trading Up 0.1%

Shares of NASDAQ:QSI opened at $0.74 on Friday. The company has a market capitalization of $161.97 million, a price-to-earnings ratio of -1.61 and a beta of 3.25. Quantum-Si has a 12 month low of $0.69 and a 12 month high of $3.10. The firm's 50-day moving average is $0.80 and its 200 day moving average is $0.89.

Quantum-Si (NASDAQ:QSI - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, equities analysts forecast that Quantum-Si will post -0.47 EPS for the current fiscal year.

Institutional Trading of Quantum-Si

A number of hedge funds have recently added to or reduced their stakes in QSI. Vanguard Group Inc. increased its position in Quantum-Si by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,714,507 shares of the company's stock valued at $12,287,000 after purchasing an additional 44,846 shares during the period. Geode Capital Management LLC lifted its position in shares of Quantum-Si by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company's stock worth $4,527,000 after purchasing an additional 367,206 shares during the period. Millennium Management LLC purchased a new stake in shares of Quantum-Si in the 1st quarter worth approximately $4,721,000. State Street Corp boosted its stake in shares of Quantum-Si by 26.5% during the fourth quarter. State Street Corp now owns 3,562,721 shares of the company's stock valued at $3,919,000 after purchasing an additional 745,231 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Quantum-Si during the third quarter valued at approximately $865,000. 39.90% of the stock is owned by hedge funds and other institutional investors.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.